Patents by Inventor Petrus Johannes SIMONS

Petrus Johannes SIMONS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190202928
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 4, 2019
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Patent number: 10273307
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 30, 2019
    Assignees: Biocerox Products B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Publication number: 20180319895
    Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.
    Type: Application
    Filed: February 23, 2018
    Publication date: November 8, 2018
    Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
  • Publication number: 20180273632
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 27, 2018
    Inventors: Petrus Johannes Simons, Louis Boon
  • Patent number: 9944717
    Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: April 17, 2018
    Assignee: Broteio Pharma B.V.
    Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
  • Publication number: 20170369586
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
  • Patent number: 9790281
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: October 17, 2017
    Assignees: BiocerOX Products, B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Publication number: 20170051069
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: August 25, 2016
    Publication date: February 23, 2017
    Inventors: Petrus Johannes Simons, Louis Boon
  • Patent number: 9475880
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 25, 2016
    Assignees: Biocerox Products, B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon
  • Publication number: 20160108134
    Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 21, 2016
    Inventors: CORNELIS ERIK HACK, CAFER YILDIZ, LOUIS BOON, PETRUS JOHANNES SIMONS
  • Publication number: 20150132288
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: September 13, 2012
    Publication date: May 14, 2015
    Applicant: BiocerOX Products B.V.
    Inventors: Petrus Johannes Simons, Louis Boon
  • Publication number: 20140377284
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: March 20, 2014
    Publication date: December 25, 2014
    Applicants: JANSSEN PHARMACEUTICALS, INC., BIOCEROX PRODUCTS B.V.
    Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG